Acadia Pharmaceuticals | ACAD - Ebit



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 3.62B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


Ebit 更改 日
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
ALKERMES USD -48.28M 37.33M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Biogen USD 514.3M 502.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 3.56B 90M 2026-03
Cara Therapeutics USD -5.94M 3.55M 2025-09
Corcept Therapeutics USD -49.6M 54.09M 2026-03
Cytokinetics USD -181.23M 2.86M 2026-03
Eisai JPY -10.31B 30.35B 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Incyte USD 344.17M 39.71M 2026-03
J&J USD 6.62B 1.51B 2026-03
Moderna USD -1.39B 531M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Pfizer USD 4.99B 340M 2026-03
Prothena USD -27.21M 12.55M 2025-12
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vanda Pharmaceuticals USD -10.28M 721K 2024-12
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03